Colloid drug-carrier systems

Muller, R. H., et al., Sohd lipid nanoparticles (SLN) an alternative colloidal drug carrier system for controlled drug debvery. Eur. J. Pharm. Biopharm., 41, 1995. 

Illing A., Unruh T., and Koch M.H.J., Investigation on particle self-assembly in solid lipid based colloidal drug carrier systems, Pharm. Res., 21, 592, 2004. 

Uner M. (2006). Preparation, characterization and physico-chemical properties of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) their benefits as colloidal drug carrier systems. Pharmazie, 61, 375-386. 

Barratt, G. Characterization of colloidal drug carrier systems with zeta potential measurements. Pharmaceutical Technology Europe 1999, 25-32. 

MUller, R. H., Davis, S. S., Ilium, L., and Mak, E. (1986). Particle charge and surface hydrophobicity of colloidal drug carriers, in Targeting of Drugs with Synthetic Systems (G. Gregoriadis, J. Senior, and G. Poste, eds.), Plenum Press,... 

Biodegradable Polymers as Drug Carriers, p. 176. Colloids and Colloid Drug Delivery System, p. 636. Dendrimers, p. 872. 

Zimmer, A, Zobel, H-P, Kumel, G, Offensberger, W-B, Noe, C R, Kreuter, J. Viral test systems for Oligonucleotide loaded colloidal drug carriers, in 2nd APG/APV World Meeting. 1998. Paris. 

Aumelas, A. Serrero, A. Durand, A. Dellacherie, E. Leonard, M. Nanoparticles of hydrophobically modified dextrans as potential drug carrier systems. Colloids Surf. B 2007, 59 (1), 74-80. 

Nanoparticles are colloidal and submicron particles generally having 10-500 nm particle size and prepared from different polymers for drug carrier systems. Drug molecules are encapsulated in nanoparticles by several methods or adsorbed on the surface of nanoparticles by electrostatic interactions. " ... 

Both oral and parenteral uptake of colloidal carrier systems have been found to depend on the nature of the carrier as such. In the latter case, the RES uptake of colloidal drug carriers depends on a number of factors, notably the surface properties of the carrier (see above). This is related to the adsorption of certain serum proteins (opsonins) at the carrier surface, which initiates various biological responses. For example, it is known that macrophages, major components in the RES system, have Fc receptors at their surfaces, which means that carriers with adsorbed IgG are more likely to be captured by these cells (52). By reducing the adsorption of the opsonins at the carrier surface, e.g. by surface treatment using PEO derivatives, a very low serum protein adsorption can be reached, thereby prolonging the bloodstream circulation time and obtaining a more uniform tissue distribution (see above). 

An interesting approach to achieve an increased uptake after oral administration of colloidal drug carriers is to use site-specific adherence through surface modification of the colloidal systems with various entities, e.g. lectins, to a selected site in the gastrointestinal tract (124). By using this approach. Lehr et al. were able to achieve an enhanced adherence of polystyrene particles to enterocytes in vitro (125). Similarly, Rubas et al. were able to enhance the uptake of liposomes into Peyer s patches in vitro through incorporation... 

---